Clinical Scorecard: Targeted Immunopharmacological Approaches for Managing Peri-implantitis: Exploring Molecular Mechanisms and Innovative Therapeutic Interventions

At a Glance

Key Highlights

• Peri-implantitis affects 8.9-45% of dental implant patients.
• Traditional treatments show limited efficacy with high recurrence rates.
• Emerging therapies include anti-cytokine biologics and macrophage-directed approaches.
• Advanced drug delivery systems like hydrogels and exosome platforms are under investigation.
• Single-cell RNA sequencing reveals distinct immune microenvironments in peri-implantitis.
• The economic burden of peri-implantitis is projected to reach $3.2 billion by 2033.

Guideline-Based Recommendations

Diagnosis

Management

• Consider host-modulatory therapies such as specialized pro-resolving mediators and targeted immunopharmacological interventions.

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Individuals with dental implants at risk for peri-implantitis.

Focus on personalized, biomarker-guided interventions.

Clinical Best Practices

• Monitor immune responses around dental implants.
• Explore advanced delivery systems for localized treatment.
• Validate emerging therapies through rigorous clinical studies.
• Assess the clinical utility of machine-learning models for risk stratification.

Related Resources & Content

• Peri-implantitis prevalence study
• Osteoimmunology research
• Single-cell RNA sequencing insights